|
1
|
Chen KS and DeLuca HF: Isolation and
characterization of a novel cDNA from HL-60 cells treated with
1,25-dihydroxyvitamin D-3. Biochim Biophys Acta. 1219:1226–1232.
1994.
|
|
2
|
Kaimul AM, Nakamura H, Masutani H and
Yodoi J: Thioredoxin and thioredoxin-binding protein-2 in cancer
and metabolic syndrome. Free Radic Biol Med. 43:861–868. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Elgort MG, O’Shea JM, Jiang Y and Ayer DE:
Transcriptional and translational downregulation of thioredoxin
interacting protein is required for metabolic reprogramming during
G(1). Genes Cancer. 1:893–907. 2010. View Article : Google Scholar
|
|
4
|
Patwari P, Chutkow WA, Cummings K, et al:
Thioredoxin-independent regulation of metabolism by the
alpha-arrestin proteins. J Biol Chem. 284:24996–25003. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Spindel ON, World C and Berk BC:
Thioredoxin interacting protein: redox dependent and independent
regulatory mechanisms. Antioxid Redox Signal. 16:587–596. 2012.
View Article : Google Scholar :
|
|
6
|
Zhou J, Yu Q and Chng WJ: TXNIP (VDUP-1,
TBP-2): a major redox regulator commonly suppressed in cancer by
epigenetic mechanisms. Int J Biochem Cell Biol. 43:1668–1673. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cadenas C, Franckenstein D, Schmidt M, et
al: Role of thioredoxin reductase 1 and thioredoxin interacting
protein in prognosis of breast cancer. Breast Cancer Res.
12:R442010. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Frullanti E, Colombo F, Falvella FS, et
al: Association of lung adenocarcinoma clinical stage with gene
expression pattern in noninvolved lung tissue. Int J Cancer.
131:E643–E648. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nishizawa K, Nishiyama H, Matsui Y, et al:
Thioredoxin-interacting protein suppresses bladder carcinogenesis.
Carcinogenesis. 32:1459–1466. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Butler LM, Zhou X, Xu WS, et al: The
histone deacetylase inhibitor SAHA arrests cancer cell growth,
up-regulates thioredoxin-binding protein-2, and down-regulates
thioredoxin. Proc Natl Acad Sci USA. 99:11700–11705. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ku WL, Girvan M, Yuan GC, Sorrentino F and
Ott E: Modeling the dynamics of bivalent histone modifications.
PLoS One. 8:e779442013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Santos-Rosa H, Schneider R, Bannister AJ,
et al: Active genes are tri-methylated at K4 of histone H3. Nature.
419:407–411. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barski A, Cuddapah S, Cui K, et al:
High-resolution profiling of histone methylations in the human
genome. Cell. 129:823–837. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chavez KJ, Garimella SV and Lipkowitz S:
Triple negative breast cancer cell lines: one tool in the search
for better treatment of triple negative breast cancer. Breast Dis.
32:35–48. 2010.
|
|
15
|
Lavarone E, Puppin C, Passon N, Filetti S,
Russo D and Damante G: The PARP inhibitor PJ34 modifies
proliferation, NIS expression and epigenetic marks in thyroid
cancer cell lines. Mol Cell Endocrinol. 365:1–10. 2013. View Article : Google Scholar
|
|
16
|
Baldan F, Lavarone E, Di Loreto C, Filetti
S, Russo D, Damante G and Puppin C: Histone post-translational
modifications induced by histone deacetylase inhibition in
transcriptional control units of NIS gene. Mol Biol Rep.
41:5257–5265. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marks PA and Xu WS: Histone deacetylase
inhibitors: potential in cancer therapy. J Cell Biochem.
107:600–608. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Russo D, Damante G, Puxeddu E, Durante C
and Filetti S: Epigenetics of thyroid cancer and novel therapeutic
targets. J Mol Endocrinol. 46:R73–R81. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou J and Chng WJ: Roles of thioredoxin
binding protein (TXNIP) in oxidative stress, apoptosis and cancer.
Mitochondrion. 13:163–169. 2013. View Article : Google Scholar
|
|
20
|
Ungerstedt JS, Sowa Y, Xu WS, et al: Role
of thioredoxin in the response of normal and transformed cells to
histone deacetylase inhibitors. Proc Natl Acad Sci USA.
102:673–678. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen A: PARP inhibitors: its role in
treatment of cancer. Chin J Cancer. 30:463–471. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamaguchi F, Hirata Y, Akram H, et al:
FOXO/TXNIP pathway is involved in the suppression of hepatocellular
carcinoma growth by glutamate antagonist MK-801. BMC Cancer.
13:4682013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Connolly R and Stearns V: Epigenetics as a
therapeutic target in breast cancer. J Mammary Gland Biol
Neoplasia. 17:191–204. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Füllgrabe J, Kavanagh E and Joseph B:
Histone onco-modifications. Oncogene. 30:3391–3403. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee JM, Hays JL, Annunziata CM, et al:
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2
mutation-associated breast or ovarian cancer with biomarker
analyses. J Natl Cancer Inst. May 19–2014.Epub ahead of print.
View Article : Google Scholar
|
|
26
|
Chu BF, Karpenko MJ, Liu Z, et al: Phase I
study of 5-aza-2′-deoxycytidine in combination with valproic acid
in non-small-cell lung cancer. Cancer Chemother Pharmacol.
71:115–121. 2013. View Article : Google Scholar
|
|
27
|
Falchook GS, Fu S, Naing A, et al:
Methylation and histone deacetylase inhibition in combination with
platinum treatment in patients with advanced malignancies. Invest
New Drugs. 31:1192–1200. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jasek E, Gajda M, Lis GJ, Jasińska M and
Litwin JA: Combinatorial effects of PARP inhibitor PJ34 and histone
deacetylase inhibitor vorinostat on leukemia cell lines. Anticancer
Res. 34:1849–1856. 2014.PubMed/NCBI
|
